Cabaletta Bio Q3 net loss widens 18% to $53.05 million
CABA•Cabaletta Bio’s third-quarter 2026 net loss widened 18% year over year to $53.05 million, while research and development expenses rose 18% to $47.14 million. The company reported $299.4 million in cash and equivalents and expects its operating runway to extend into the first quarter of 2028.
1. Quarterly results and outlook
Cabaletta Bio reported a third-quarter 2026 net loss of $53.05 million, up 18% year over year, and research and development expenses of $47.14 million, also up 18%. Cash and cash equivalents totaled $299.4 million at September 30, supporting an operating runway into the first quarter of 2028. The company expects registrational myositis topline results in the second half of 2027 and plans a BLA submission in the first quarter of 2028; a registrational systemic sclerosis cohort targeting patients with interstitial lung disease opened for enrollment.
